# Celcuity (CELC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CELC
## Company Profile
- Ticker: CELC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 63.19 USD
- Market cap: 4458214048.96 USD
- Last updated: 2026-10-13
## Business Overview
### PAM Pathway Oncology
Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth.
### REVTORPYK
REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
### VIKTORIA-1
The Phase 3 VIKTORIA-1 program evaluates gedatolisib combinations after progression on endocrine therapy. Positive results in both PIK3CA wild-type and mutant cohorts support expansion of the approved population.
### First-Line Development
VIKTORIA-2 evaluates gedatolisib regimens in the first-line advanced breast-cancer setting, including endocrine-sensitive and endocrine-resistant patient populations.
## Why The Stock Is Moving

As of Oct 13, 2026, CELC closed down 4.04% at $63.19. No new same-company headline was identified in the current news window.

## Future Catalysts

- Submission of an sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer in the third quarter of 2026.
- Commercial launch of REVTORPYK in late third-quarter 2026.

## Recent News
- 2026-10-05 12:00 EST — [Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/CELC/celcuity-announces-multiple-presentations-at-the-european-society-for-medical-on-838dcc02) — Source: Celcuity
- 2026-10-02 12:00 EST — [Celcuity Appoints David Gryska To Its Board Of Directors](https://biopharmsignal.com/news/CELC/celcuity-appoints-david-gryska-to-its-board-of-directors-fd28e0f5) — Source: Celcuity
- 2026-09-30 12:00 EST — [Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States](https://biopharmsignal.com/news/CELC/celcuity-announces-that-revtorpyk-gedatolisib-is-now-commercially-available-in-t-9eff9999) — Source: Celcuity
- 2026-09-01 12:30 EST — [Celcuity To Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CELC/celcuity-to-participate-in-upcoming-investor-conferences-11e1b860) — Source: Celcuity
- 2026-08-26 12:30 EST — [Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer](https://biopharmsignal.com/news/CELC/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-116bbf02) — Source: Celcuity